Please click on the video to start the presentation. While watching the presentation, you can also click on each of the small slides to jump to the sections. We appreciate your feedback: Please rate the video with the radio buttons above, share your comments using comments box below, or share your ideas in our Discussion Forum. View the other Virtual Education Program modules.

Issues covered in this presentation:

• Definition of optimal response to imatinib
• Suboptimal response
• Considerations for managing suboptimal response, case study
• Adherence and molecular response
• Role of mutations, criteria for mutation screening on first line therapy
• Dose related toxicities with TKI’s; concomitant medications

Has this been helpful? Please provide your comments here: